Avian and pandemic influenza

An overview

Gregory A. Poland, Robert M. Jacobson, Paul V. Targonski

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Influenza A/H5N1 (avian influenza) has now caused 258 human infections (as of November 13, 2006), with an approximate 50% mortality rate. Because the virus is novel in terms of antigenic type and causes infection and illness, and because humans have no pre-existing immunity, the conditions for a possible pandemic exist. Additionally, wild migratory birds appear to be spreading the virus across ever larger geographic areas, and newer clade 2 influenza A/H5N1 viruses have begun to emerge. The US Congressional Budget Office has formally modeled the likely consequences of pandemic influenza and estimates that up to 2 million of the US population might die, with up to 40% of all workers ill for as long as 3 or more weeks. This brief overview will review basic virologic, immunologic and epidemiologic information relevant to understanding and preparing for this threat. In particular, the role of avian influenza vaccines will be reviewed.

Original languageEnglish (US)
Pages (from-to)3057-3061
Number of pages5
JournalVaccine
Volume25
Issue number16 SPEC. ISS.
DOIs
StatePublished - Apr 20 2007

Fingerprint

Influenza in Birds
Pandemics
pandemic
influenza
Human Influenza
avian influenza
H5N1 Subtype Influenza A Virus
Viruses
Preexisting Condition Coverage
Influenza Vaccines
Influenza A virus
Budgets
Infection
Birds
Immunity
viruses
wild birds
infection
Mortality
immunity

Keywords

  • Avian influenza
  • Pandemic influenza

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Poland, G. A., Jacobson, R. M., & Targonski, P. V. (2007). Avian and pandemic influenza: An overview. Vaccine, 25(16 SPEC. ISS.), 3057-3061. https://doi.org/10.1016/j.vaccine.2007.01.050

Avian and pandemic influenza : An overview. / Poland, Gregory A.; Jacobson, Robert M.; Targonski, Paul V.

In: Vaccine, Vol. 25, No. 16 SPEC. ISS., 20.04.2007, p. 3057-3061.

Research output: Contribution to journalArticle

Poland, GA, Jacobson, RM & Targonski, PV 2007, 'Avian and pandemic influenza: An overview', Vaccine, vol. 25, no. 16 SPEC. ISS., pp. 3057-3061. https://doi.org/10.1016/j.vaccine.2007.01.050
Poland GA, Jacobson RM, Targonski PV. Avian and pandemic influenza: An overview. Vaccine. 2007 Apr 20;25(16 SPEC. ISS.):3057-3061. https://doi.org/10.1016/j.vaccine.2007.01.050
Poland, Gregory A. ; Jacobson, Robert M. ; Targonski, Paul V. / Avian and pandemic influenza : An overview. In: Vaccine. 2007 ; Vol. 25, No. 16 SPEC. ISS. pp. 3057-3061.
@article{bda4d4da75b444f8bd8a6091ef0c7925,
title = "Avian and pandemic influenza: An overview",
abstract = "Influenza A/H5N1 (avian influenza) has now caused 258 human infections (as of November 13, 2006), with an approximate 50{\%} mortality rate. Because the virus is novel in terms of antigenic type and causes infection and illness, and because humans have no pre-existing immunity, the conditions for a possible pandemic exist. Additionally, wild migratory birds appear to be spreading the virus across ever larger geographic areas, and newer clade 2 influenza A/H5N1 viruses have begun to emerge. The US Congressional Budget Office has formally modeled the likely consequences of pandemic influenza and estimates that up to 2 million of the US population might die, with up to 40{\%} of all workers ill for as long as 3 or more weeks. This brief overview will review basic virologic, immunologic and epidemiologic information relevant to understanding and preparing for this threat. In particular, the role of avian influenza vaccines will be reviewed.",
keywords = "Avian influenza, Pandemic influenza",
author = "Poland, {Gregory A.} and Jacobson, {Robert M.} and Targonski, {Paul V.}",
year = "2007",
month = "4",
day = "20",
doi = "10.1016/j.vaccine.2007.01.050",
language = "English (US)",
volume = "25",
pages = "3057--3061",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "16 SPEC. ISS.",

}

TY - JOUR

T1 - Avian and pandemic influenza

T2 - An overview

AU - Poland, Gregory A.

AU - Jacobson, Robert M.

AU - Targonski, Paul V.

PY - 2007/4/20

Y1 - 2007/4/20

N2 - Influenza A/H5N1 (avian influenza) has now caused 258 human infections (as of November 13, 2006), with an approximate 50% mortality rate. Because the virus is novel in terms of antigenic type and causes infection and illness, and because humans have no pre-existing immunity, the conditions for a possible pandemic exist. Additionally, wild migratory birds appear to be spreading the virus across ever larger geographic areas, and newer clade 2 influenza A/H5N1 viruses have begun to emerge. The US Congressional Budget Office has formally modeled the likely consequences of pandemic influenza and estimates that up to 2 million of the US population might die, with up to 40% of all workers ill for as long as 3 or more weeks. This brief overview will review basic virologic, immunologic and epidemiologic information relevant to understanding and preparing for this threat. In particular, the role of avian influenza vaccines will be reviewed.

AB - Influenza A/H5N1 (avian influenza) has now caused 258 human infections (as of November 13, 2006), with an approximate 50% mortality rate. Because the virus is novel in terms of antigenic type and causes infection and illness, and because humans have no pre-existing immunity, the conditions for a possible pandemic exist. Additionally, wild migratory birds appear to be spreading the virus across ever larger geographic areas, and newer clade 2 influenza A/H5N1 viruses have begun to emerge. The US Congressional Budget Office has formally modeled the likely consequences of pandemic influenza and estimates that up to 2 million of the US population might die, with up to 40% of all workers ill for as long as 3 or more weeks. This brief overview will review basic virologic, immunologic and epidemiologic information relevant to understanding and preparing for this threat. In particular, the role of avian influenza vaccines will be reviewed.

KW - Avian influenza

KW - Pandemic influenza

UR - http://www.scopus.com/inward/record.url?scp=33947603212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947603212&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.01.050

DO - 10.1016/j.vaccine.2007.01.050

M3 - Article

VL - 25

SP - 3057

EP - 3061

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 16 SPEC. ISS.

ER -